vs
HeartSciences Inc.（HSCS）与Algorhythm Holdings, Inc.（RIME）财务数据对比。点击上方公司名可切换其他公司
Algorhythm Holdings, Inc.净利率更高（169.1% vs -97179.4%，领先97348.5%）
迈瑞尔生命科学是一家总部位于印度古吉拉特邦瓦皮的跨国医疗器械企业，隶属于比拉基亚集团，2006年成立。公司主营血管介入器械、骨科植入物、外科手术器械、耳鼻喉科产品及体外诊断试剂的研发生产，业务覆盖全球150余个国家，截至2024年共有员工1万人。
Algorhythm Holdings是一家专注于医疗领域人工智能临床决策支持解决方案的科技公司，主要服务北美地区医疗机构，旗下产品可提升诊疗质量、简化临床工作流程、降低运营成本。
HSCS vs RIME — 直观对比
营收规模更大
HSCS
是对方的-0.0倍
$-2.1M
净利率更高
RIME
高出97348.5%
-97179.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.4K | $-2.1M |
| 净利润 | $-2.4M | $-3.5M |
| 毛利率 | 58.3% | 117.3% |
| 营业利润率 | -85713.2% | 135.4% |
| 净利率 | -97179.4% | 169.1% |
| 营收同比 | — | 56.1% |
| 净利润同比 | -12.9% | 78.2% |
| 每股收益（稀释后） | $-0.85 | $-0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSCSRIME
| Q4 25 | $2.4K | $-2.1M | ||
| Q3 25 | $1.9K | — | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | $0 | — | ||
| Q4 24 | — | $-4.7M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | $14.7K | $2.4M | ||
| Q4 23 | $3.9K | — |
净利润HSCSRIME
| Q4 25 | $-2.4M | $-3.5M | ||
| Q3 25 | $-2.1M | — | ||
| Q2 25 | — | $-809.0K | ||
| Q1 25 | $-2.5M | — | ||
| Q4 24 | — | $-16.0M | ||
| Q2 24 | — | $-6.1M | ||
| Q1 24 | $-1.6M | $-2.4M | ||
| Q4 23 | $-1.7M | — |
毛利率HSCSRIME
| Q4 25 | 58.3% | 117.3% | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | — | 35.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | 69.0% | 20.7% | ||
| Q4 23 | 61.0% | — |
营业利润率HSCSRIME
| Q4 25 | -85713.2% | 135.4% | ||
| Q3 25 | -98637.8% | — | ||
| Q2 25 | — | -28.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | -252.2% | ||
| Q1 24 | -10376.7% | -94.3% | ||
| Q4 23 | -40254.9% | — |
净利率HSCSRIME
| Q4 25 | -97179.4% | 169.1% | ||
| Q3 25 | -108157.6% | — | ||
| Q2 25 | — | -29.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 340.0% | ||
| Q2 24 | — | -250.8% | ||
| Q1 24 | -11182.4% | -97.6% | ||
| Q4 23 | -44830.2% | — |
每股收益（稀释后）HSCSRIME
| Q4 25 | $-0.85 | $-0.36 | ||
| Q3 25 | $-1.58 | — | ||
| Q2 25 | — | $-0.24 | ||
| Q1 25 | $-2.57 | — | ||
| Q4 24 | — | $-89.56 | ||
| Q2 24 | — | $-190.68 | ||
| Q1 24 | $-3.01 | $-73.76 | ||
| Q4 23 | $-15.92 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $-1.9M |
| 总资产 | $6.0M | $12.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HSCSRIME
| Q4 25 | $2.0M | — | ||
| Q3 25 | $2.8M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $2.6M | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | $7.1M | $4.1M | ||
| Q4 23 | $100.1K | — |
股东权益HSCSRIME
| Q4 25 | $4.2M | $-1.9M | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | — | $2.8M | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | — | $-10.5M | ||
| Q2 24 | — | $-872.0K | ||
| Q1 24 | $8.6M | $5.2M | ||
| Q4 23 | $-1.6M | — |
总资产HSCSRIME
| Q4 25 | $6.0M | $12.7M | ||
| Q3 25 | $6.4M | — | ||
| Q2 25 | — | $12.7M | ||
| Q1 25 | $5.7M | — | ||
| Q4 24 | — | $18.3M | ||
| Q2 24 | — | $12.4M | ||
| Q1 24 | $10.8M | $19.9M | ||
| Q4 23 | $2.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.3M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流HSCSRIME
| Q4 25 | $-2.3M | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | — | $-1.5M | ||
| Q2 24 | — | $-2.9M | ||
| Q1 24 | $-2.1M | $-2.6M | ||
| Q4 23 | $-988.2K | — |
自由现金流HSCSRIME
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-990.1K | — |
自由现金流率HSCSRIME
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -14352.1% | — | ||
| Q4 23 | -25388.2% | — |
资本支出强度HSCSRIME
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 59.8% | — | ||
| Q4 23 | 50.1% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
